Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

The placebo-controlled, double-blind, randomised Phase I trial involved 100 healthy participants.

In a new publication, researchers from the German Center for Diabetes Research (DZD) and the University of Medicine ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

Jen Lamppa, VP of Commercial Strategy at Inovalon, says that RWD will be held to the same scrutiny as trial data if used in ...

Licensed scientific and clinical intelligence integrated into the 3RnD platform to support AI-Driven Discovery and ...

A cohort study finds the risk for acne in patients on JAK inhibitors for atopic dermatitis was about 2.5 times greater than ...

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

New research opens the door for more streamlined and patient-centric protocols, informed by benchmarking analysis of phase II and III protocol procedures The research assesses how protocol design ...

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027. Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be rep ...

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the ...

New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial ...